hydroxyurea has been researched along with pomalidomide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Brady, H; Chan, K; Corral, LG; Ferguson, GD; Glezer, E; Jensen-Pergakes, K; Morris, CL; Moutouh-de Parseval, LA; Muller, G; Verhelle, D | 1 |
| Corral, LG; Kutlar, A; Kutlar, F; Meiler, SE; Moutouh-de Parseval, LA; Swerdlow, PS; Wade, M; Xue, Y; Yerigenahally, SD | 1 |
| Abdulmalik, O; Blobel, GA; Giardine, BM; Hardison, RC; Huang, P; Keller, CA; Khandros, E; Peslak, SA; Sharma, M; Zhang, Z | 1 |
3 other study(ies) available for hydroxyurea and pomalidomide
| Article | Year |
|---|---|
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
Topics: Anemia, Sickle Cell; Antigens, CD34; Antineoplastic Agents; Antisickling Agents; beta-Thalassemia; Blood Transfusion; Cells, Cultured; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Synergism; Erythroid Cells; Erythropoiesis; Fetal Hemoglobin; Humans; Hydroxyurea; Lenalidomide; Models, Biological; Thalidomide; Up-Regulation | 2008 |
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.
Topics: Anemia, Sickle Cell; Animals; Antisickling Agents; Bone Marrow; Disease Models, Animal; Erythropoiesis; Fetal Hemoglobin; Hydroxyurea; Mice; Mice, Knockout; Mice, Transgenic; Thalidomide | 2011 |
Understanding heterogeneity of fetal hemoglobin induction through comparative analysis of F and A erythroblasts.
Topics: Adult; Anemia, Sickle Cell; Cell Line; Cell Separation; Cells, Cultured; Erythroblasts; Erythroid Cells; Fetal Hemoglobin; Gene Expression Profiling; Hemoglobin A; Humans; Hydroxyurea; Proteomics; RNA, Messenger; Thalidomide | 2020 |